Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2015) 4 P93 | DOI: 10.1530/boneabs.4.P93

ICCBH2015 Poster Presentations (1) (201 abstracts)

Improving low bone mass in girls with adolescent idiopathic scoliosis (AIS) using calcium and vitamin D supplementation -- a randomized controlled trial

Tsz Ping Lam 1 , Benjamin Hon Kei Yip 1 , Fiona Wai Ping Yu 1 , Echo Ka Ling Tsang 1 , Kenneth Kin Wah To 2 , Yuk Wai Lee 1 , Lyn Lee Ning Wong 1 , Kwong Man Lee 3 , Bobby Kin Wah Ng 1 & Jack Chun Yiu Cheng 1


1Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, Hong Kong; 2School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong; 3Lee Hysan Clinical Research Laboratories, The Chinese University of Hong Kong, Shatin, Hong Kong.


Objectives: AIS is a prevalent three-dimensional spinal deformity associated with low bone mass which has been reported to be a significant prognostic factor for curve progression in AIS. If left untreated, low bone mass in AIS could persist into adulthood thus leading to subsequent health problems. This study aimed at evaluating the therapeutic effect of oral calcium plus Vit-D supplementation for low bone mass in skeletally immature AIS girls.

Methods: This was a randomized double-blinded placebo-controlled trial recruiting AIS girls (11–14 years old, Tanner < IV) with BMD z-scores<0 and Cobb angle >15°. 330 subjects were randomly allocated to group1 (placebo), group2 (600 mg Calcium+400 IU Vit-D3 per day) and group 3 (600 mg Calcium+800 IU Vit-D3 per day). The study period was 2 years. At baseline (T0) and 24-month (T1) time-point, aBMD and BMC at bilateral femoral necks were measured with dual-energy x-ray absorptiometry (DXA); and serum 25(OH) Vit-D level with liquid chromatography tandem mass spectrometry. intention-to-treat principle was followed. ANOVA and generalized estimating equations were used for analyses.

Results: The baseline data at T0 are shown in Table 1. The corresponding mean % increases at T1 are shown in Table 2. The gain in right and left aBMD and BMC were significantly greater in the treatment group than the placebo group (Table 2).

Table 1 Baseline data on Age, 25(OH)VitD3 and DXA parameters
mean±S.D. at T0
Group 1 N=110Group 2 N=110Group 3 N=110P#
Age13.0±0.8612.9±0.9112.7±0.880.142
25(OH) Vit-D341.4±13.342.3±14.339.4±15.40.306
Left BMD0.683±0.0590.677±0.0710.673±0.0660.500
Right BMD0.694±0.0640.681±0.0680.677±0.0650.126
Left BMC1.917±0.2211.924±0.2371.904±0.2320.810
Right BMC1.960±0.2541.940±0.2441.928±0.2170.601
#P-value from analysis using one-way ANOVA
Table 2 Percentage increase on 25(OH) Vit-D3 and DXA parameters from T0 to T1 for group 1, group 2 and group 3
Percentage increase at T1 mean±S.D.P*
Group 1 N=91Group 2 N=91Group 3 N=88Group 1 vs group 2Group 1 vs group 3Group 2 vs group 3
25(OH) Vit-D322.3±47.062.4±65.197.0±88.0<0.001<0.001<0.001
Left BMD10.7±6.713.0±7.013.6±8.30.02370.0055>0.20
Right BMD10.3±6.712.8±7.013.4±8.30.0290.020>0.20
Left BMC13.8±8.816.0±8.617.9±11.30.04210.0013>0.20
Right BMC12.5±8.515.5±10.016.8±10.40.03660.0018>0.20
*P-value from analysis using generalized estimating equations

Conclusion: The results provided strong evidences that treatment with 600 mg calcium+400/800 IU Vit-D3 was effective for treating low bone mass in AIS subjects having z-score<0. Given the suboptimal 25(OH) Vit-D levels detected in this study and the association between AIS and low bone mass, Vit-D status and bone mineral density should be assessed and be followed as indicated by calcium+Vit-D supplementation for all AIS subjects.

Funding source: This study was partially funded by an Investigator Initiated Research grant from Pfizer Inc (IIR Grant No. WI 174540).

Disclosure: The authors declared no competing interests.

Volume 4

7th International Conference on Children's Bone Health

Salzburg, Austria
27 Jun 2015 - 30 Jun 2015

ICCBH 

Browse other volumes

Article tools

My recent searches

No recent searches.